Retatrutide vs Zepbound (2026): Pipeline Drug vs FDA-Approved
Retatrutide (retatrutide (LY3437943), Eli Lilly) vs Zepbound (tirzepatide, Eli Lilly)
Last verified November 2026
The verdict
Retatrutide (LY3437943) and Zepbound (tirzepatide) are both developed by Eli Lilly, but they sit at opposite ends of the regulatory spectrum: Zepbound is FDA-approved and commercially available for chronic weight management, while retatrutide is an investigational triple agonist whose first phase 3 obesity trials were published in 2026. Cross-trial comparison suggests retatrutide may produce somewhat greater weight loss: 24.2% at 48 weeks in phase 2 (12 mg; N=81 in that arm) versus Zepbound's 20.9% at 72 weeks in SURMOUNT-1 (15 mg; N=630 in that arm), and TRIUMPH-1 (NEJM 2026) has since reported up to 25.0% at 80 weeks. Lilly's first head-to-head, TRANSCEND-T2D-2, compared retatrutide with Ozempic 2 mg rather than Zepbound: weight fell 19.5% (9 mg) and 20.9% (12 mg) versus 9.4% at 80 weeks in company topline data that are not yet peer-reviewed. Without a trial against tirzepatide, no superiority claim over Zepbound is warranted; our retatrutide vs tirzepatide evidence review sets out what is known. For patients who need treatment today, Zepbound is the only evidence-backed and legally obtainable option, and the retatrutide approval timeline shows when that could change.
Side-by-side comparison
| Field | Retatrutide | Zepbound |
|---|---|---|
| Peak weight loss (trial) | −24.2% at 48 wk (Phase 2, 12 mg; N=81 in highest-dose arm) | −20.9% at 72 wk (SURMOUNT-1, 15 mg; Phase 3, N=630 in that arm) |
| Mechanism | Triple agonist: GLP-1, GIP, and glucagon receptors | Dual agonist: GLP-1 and GIP receptors |
| FDA status | Not FDA-approved; BLA submission planned Q1 2027 | FDA approved November 2023 for chronic weight management in adults |
| Trial stage | Phase 3 (TRIUMPH-1 and TRIUMPH-2 published 2026; BLA submission planned Q1 2027) | Phase 3 complete (SURMOUNT program); full regulatory approval granted |
| Availability | Not available; accessible through TRIUMPH clinical trials (clinicaltrials.gov) only | Commercially available by prescription in the United States |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (2.5 mg–15 mg titrated dose) |
| GI side effects | Dose-related nausea, vomiting, diarrhea; mostly mild–moderate in Phase 2; dose-dependent heart rate increase (peaked wk 24, declined thereafter) | Nausea, vomiting, diarrhea, constipation; mild–moderate, mainly during dose escalation; discontinuation rate 4.3–7.1% |
Frequently asked questions
Is retatrutide better than Zepbound for weight loss?
Retatrutide's Phase 2 data (−24.2% at 48 weeks, 12 mg) numerically exceeded Zepbound's Phase 3 results (−20.9% at 72 weeks, 15 mg), but a direct head-to-head trial does not exist. Phase 2 trials often overestimate efficacy compared to larger Phase 3 trials, and the retatrutide comparison arm was small (N=81). TRIUMPH-1 has since reported up to 25.0% at 80 weeks, but no trial has compared retatrutide with tirzepatide, so no superiority claim is justified.
When will retatrutide be available?
Not in 2026. TRIUMPH-1 and TRIUMPH-2 were published in 2026, and Eli Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Launch timing depends on the FDA's review. Until then, retatrutide is available only through clinical trials and a narrow single-patient expanded access program (NCT07629401) requested by a physician.
Can I switch from Zepbound to retatrutide?
Not outside of a clinical trial. Retatrutide is not FDA-approved as of November 2026. If you are responding well to Zepbound, continuing treatment is recommended. Discuss TRIUMPH trial eligibility with your doctor if you are interested in accessing retatrutide experimentally.
Why did Eli Lilly develop retatrutide if they already have Zepbound?
Retatrutide adds glucagon receptor agonism to the GLP-1 + GIP dual mechanism in tirzepatide (Zepbound). Glucagon signaling may increase energy expenditure beyond what dual agonism achieves, potentially pushing weight loss above 25–30%. Eli Lilly is developing retatrutide as a potential next-generation therapy for patients who need greater efficacy.
Does retatrutide work for type 2 diabetes like Zepbound (Mounjaro)?
Zepbound (tirzepatide) is also FDA-approved as Mounjaro for type 2 diabetes. Retatrutide's glucagon receptor activity theoretically could raise blood glucose in some patients, a concern that is being evaluated in Phase 3. Phase 2 data showed favorable glycemic effects overall. For T2D today, Mounjaro/Zepbound is the proven and approved choice.
What are the side effects of retatrutide compared to Zepbound?
Both drugs share GLP-1-related GI side effects: nausea, vomiting, diarrhea, and constipation. In retatrutide's Phase 2 trial, these were dose-related and mostly mild to moderate, and were partially mitigated by a lower starting dose (2 mg versus 4 mg). Retatrutide also caused dose-dependent heart rate increases that peaked at week 24 and declined — a pattern seen with other incretins. The full safety profile will not be established until Phase 3 is complete.
References
- 1.Jastreboff AM, Kaplan LM, Frías JP, et al.; Retatrutide Phase 2 Obesity Trial Investigators Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial N Engl J Med. 2023. PMID: 37366315.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators Tirzepatide Once Weekly for the Treatment of Obesity N Engl J Med. 2022. PMID: 35658024.
- 3.Giblin K, Bethel MA, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes Obes Metab. 2026. PMID: 41090431.
- 4.Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity N Engl J Med. 2026. PMID: 42814954.
- 5.Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K exhibit) U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
- 6.Eli Lilly and Company Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial PR Newswire. 2026. https://www.prnewswire.com/news-releases/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-the-weight-loss-of-ozempics-highest-approved-dose-in-head-to-head-trial-302921328.html
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.